Virtual reality mindfulness for hard-to-treat depression
Part of Mental health clinical trials.
This study tests whether using a virtual reality mindfulness program, added to your usual depression care, can help people whose depression hasn't responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 74 years old.
- You have major depression that hasn't improved with at least two different antidepressant medications.
- You have also tried combining or adding another antidepressant to your treatment without success.
- You are not currently taking part in another study for depression medication.
- You do not have any medical condition that would make esketamine unsafe for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a virtual reality program can help older adults with depression become more active and feel better. You would use a VR headset at home to practice activities that improve your mood.
This trial tests if adding virtual reality to ketamine treatments can help people with depression that hasn't improved with other treatments. You'll receive IV ketamine as prescribed by your doctor and also use a virtual reality headset during sessions.
This trial tests if adding a type of talk therapy called integration therapy helps esketamine work better for people with depression that hasn't improved with other treatments. You'll receive esketamine, and some people also get guided sessions to reflect on their experiences.
This trial tests a new approach that combines virtual reality (VR) with a psychedelic-like experience to help people with depression. The therapy is designed to be used safely in a clinic and aims to improve mood and well-being.
This trial tests how treatment with esketamine affects metabolism in people with depression. It may help if you have not responded to at least two standard antidepressants.
This study tests whether esketamine, a nasal spray for depression, can help adults whose depression has not improved with at least two other antidepressants. Participants continue their current treatment while receiving esketamine.
Hear when a new Depression - Major Depressive Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.